The study (NCT04856982), called ATLAS, is a randomized, placebo-controlled phase 3 trial with a longitudinal natural history run-in designed to evaluate whether intrathecal injections of BIIB067 (tofersen), an antisense oligonucleotide (ASO) designed to reduce SOD1 synthesis [86, 87], can delay the emergence of clinically manifest ALS. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.